# Immatics N.V. (IMTX)

- Sector: Healthcare · Industry: Biotechnology
- SEC CIK: 0001809196 ([filings on EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001809196))
- Full page: https://inspectstocks.com/stocks/imtx
- Data as of: price 2026-09-25; newest filing used 2026-08-18; latest fiscal period ended 2026-06-30

## Grade

Not rated: fewer than four of the five checks could be answered from the filings. This is not the same as a failing grade.

How the grade works: the letter counts failed checks (none → A, one → B, two → C, three → D, four or more → F). It is built from SEC filings only — the share price never enters it — and describes the business, not whether the stock is worth buying.

## Key figures

In US dollars, converted from EUR at today's spot rate (every period alike).

| Measure | Value |
| --- | --- |
| Net income, trailing twelve months | -$235M |
| Free cash flow, trailing twelve months | -$208.4M |
| Return on equity | -42.7% |
| Debt to equity | 0.03 |
| Diluted EPS, trailing twelve months | -$1.81 |
| Share price | $8.37 |
| Market value | $1.1B |

## More on this company

- [Overview](https://inspectstocks.com/stocks/imtx)
- [Financial statements](https://inspectstocks.com/stocks/imtx/financials)
- [Competitors](https://inspectstocks.com/stocks/imtx/peers)
- [Earnings](https://inspectstocks.com/stocks/imtx/earnings)

---

Source: InspectStocks, built from the company’s own SEC filings. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.